We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Promising Biomarker Discovered for Esophageal Cancer

By LabMedica International staff writers
Posted on 28 May 2014
A new biomarker for esophageal cancer shows promise in improving screening for this deadly disease and its precursor, Barrett's esophagus. More...


Barrett's esophagus (BE) is a leading predictor of esophageal cancer and compared with the general population, patients with BE have an 11-fold higher risk of developing adenocarcinoma of the esophagus.

Scientists at Case Western Reserve University Hospital (Cleveland, OH, USA) examined if a new, non-endoscopic "brushing" of the esophagus is as effective as the more invasive, traditional biopsy. The team based their study on aberrant vimentin methylation, a highly common epigenetic alteration in neoplasia of the upper gastrointestinal tract. They analyzed esophageal specimens in patients with BE, esophageal cancer as well as control subjects. The data determined that methylated vimentin is a highly sensitive biomarker for Barrett's esophagus and that the less invasive brushing technique can effectively detect these changes in the DNA.

Amitabh Chak, MD, who presented the findings, said, “Despite the fact that the rates of common cancers have declined in recent years, esophageal cancer has a poor five-year survival rate of less than 15%. Early detection through screening can prevent the development of esophageal cancer. This promising new test has important clinical implications through its potential to improve screening and decrease mortality from this deadly disease. This is true translational research, bringing a discovery from the laboratory to the patient care setting. This new technique to sensitively detect changes in the DNA may have significant implication for the clinical practice of screening and primary prevention of esophageal cancer.”

Sanford Markowitz, MD, an oncologist at Case Western Reserve University Hospital, said, “Our team's hope is that the use of molecular markers for non-endoscopic screening will drive down the cost and increase the ease of screening for these early esophageal lesions that can give rise to cancer. Longer term we hope to find additional markers that will allow the same approach to be used in the monitoring of Barrett's patients to detect early progression to more advanced disease.” Barrett's esophagus affects up to 6.8% of the population. The study was presented at the Digestive Disease Week (DDW) Annual Meeting held May 3–6, 2014, in Chicago (IL, USA).

Related Links:

Case Western Reserve University Hospital




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.